Literature DB >> 16912693

Melanocortin receptor ligands: new horizons for skin biology and clinical dermatology.

Markus Böhm1, Thomas A Luger, Desmond J Tobin, José Carlos García-Borrón.   

Abstract

The melanocortin (MC) system is probably the best characterized neuropeptide network of the skin. Most cutaneous cell types express MC receptors (MC-Rs) and synthesize MCs, such as alpha-melanocyte-stimulating hormone (alpha-MSH), that act in autocrine and paracrine fashion. In human skin cells, activation of adenylate cyclase by MCs occurs at 10(-6)-10(-9) M doses of the ligand, but effects are induced in some cell types at subnanomolar concentrations. In addition to the pigmentary action of MCs on epidermal melanocytes, the hair follicle is a source and target for MCs. MCs regulate lipogenesis in sebocytes expressing both MC-1R and MC-5R. In adipocytes, lipid metabolism is modulated by agouti signalling protein, a natural MC-1R/MC-4R antagonist. The anti-inflammatory activity of alpha-MSH includes immunomodulatory effects on several resident skin cells and antifibrogenic effects mediated via MC-1R expressed by dermal fibroblasts. In human mast cells, alpha-MSH appears to be proinflammatory due to histamine release. alpha-MSH exhibits cytoprotective activity against UVB-induced apoptosis and DNA damage, a finding that helps explain the increased risk of cutaneous melanoma in individuals with loss of function MC-1R mutations. These findings should improve our understanding of skin physiology and pathophysiology and may offer novel strategies with MCs as future therapeutics for skin diseases.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16912693     DOI: 10.1038/sj.jid.5700421

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  46 in total

1.  Radiofluorinated rhenium cyclized α-MSH analogues for PET imaging of melanocortin receptor 1.

Authors:  Gang Ren; Shuanlong Liu; Hongguang Liu; Zheng Miao; Zhen Cheng
Journal:  Bioconjug Chem       Date:  2010-11-12       Impact factor: 4.774

2.  Melanoma resistance: a bright future for academicians and a challenge for patient advocates.

Authors:  Andrzej T Slominski; J Andrew Carlson
Journal:  Mayo Clin Proc       Date:  2014-04       Impact factor: 7.616

3.  A nervous breakdown in the skin: stress and the epidermal barrier.

Authors:  Andrzej Slominski
Journal:  J Clin Invest       Date:  2007-11       Impact factor: 14.808

4.  An α-MSH analog in erythropoietic protoporphyria.

Authors:  Thomas A Luger; Markus Böhm
Journal:  J Invest Dermatol       Date:  2015-04       Impact factor: 8.551

Review 5.  MC1R, the cAMP pathway, and the response to solar UV: extending the horizon beyond pigmentation.

Authors:  Jose C García-Borrón; Zalfa Abdel-Malek; Celia Jiménez-Cervantes
Journal:  Pigment Cell Melanoma Res       Date:  2014-05-30       Impact factor: 4.693

6.  Diminishment of alpha-MSH anti-inflammatory activity in MC1r siRNA-transfected RAW264.7 macrophages.

Authors:  Dayu Li; Andrew W Taylor
Journal:  J Leukoc Biol       Date:  2008-04-03       Impact factor: 4.962

7.  On the role of the corticotropin-releasing hormone signalling system in the aetiology of inflammatory skin disorders.

Authors:  A Slominski
Journal:  Br J Dermatol       Date:  2009-02       Impact factor: 9.302

8.  Aging of the hair follicle pigmentation system.

Authors:  Desmond J Tobin
Journal:  Int J Trichology       Date:  2009-07

9.  The role of melanogenesis in regulation of melanoma behavior: melanogenesis leads to stimulation of HIF-1α expression and HIF-dependent attendant pathways.

Authors:  A Slominski; T-K Kim; A A Brożyna; Z Janjetovic; D L P Brooks; L P Schwab; C Skobowiat; W Jóźwicki; T N Seagroves
Journal:  Arch Biochem Biophys       Date:  2014-07-02       Impact factor: 4.013

10.  Pigmentation and vitamin D metabolism in Caucasians: low vitamin D serum levels in fair skin types in the UK.

Authors:  Daniel Glass; Marko Lens; Ramasamyiyer Swaminathan; Tim D Spector; Veronique Bataille
Journal:  PLoS One       Date:  2009-08-03       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.